x

Achieving lactose-free targets faster than ever

Date: 01.06.2023Source: dsm-firmenich

dsm-firmenich has launched Maxilact®Next – the latest addition to its highly-valued range of efficient and pure Maxilact® lactase enzymes. With the new Maxilact®Next, dsm-firmenich introduces a lactase that produces lactose-free milk even faster, allowing its customers to achieve an additional 25% reduction in hydrolysis time. Maxilact®Next is the fastest pure lactase now available on the market which empowers lactose-free milk producers to optimise production, increase capacity and use raw materials more efficiently – all without affecting the taste of lactose-free milk products. It joins the existing Maxilact® range, an extensive portfolio based on the company’s more than 50 years’ experience leading lactose-free dairy production.

With 70% of consumers worldwide unable to properly digest lactose, lactose-free products are vital for ensuring everyone can fully enjoy great tasting, nutritious dairy products. Forecasts predict that lactose-free dairy will achieve a CAGR more than double that of regular dairy between 2022 and 2026, eventually exceeding a value of €10.6 billion. This creates fresh opportunities for dairy producers while also emphasising the need for a swifter and more efficient production process. Manufacturers require first-class lactase solutions to optimise their raw material usage, increase yield and productivity and maintain the highest quality standards.

Said Rodolfo Garza, Global Business Development Manager Milk & Plant-Based Alternatives, dsm-firmenich: “We’re proud to introduce Maxilact®Next to the market – the fastest, purest, most efficient lactase enzyme solution in our portfolio yet. In the current market context, efficiency is crucial to keep up with demand and stay cost effective. Our Maxilact® range delivers optimised capacity without significant capex investment while maintaining the high quality that consumers expect. Maxilact®Next is a great example of a game-changing lactase solution which truly addresses a market pain point.”

dsm-firmenich’s extensive selection of Maxilact® enzymes along with its portfolio of cultures, probiotics, vitamins, minerals and more allows manufacturers to produce lactose-free products that are not only more efficient but also more delicious and nutritious, catering to the ever-expanding global consumer base.  For more visit dsm.com/food-beverage/en_US/markets/dairy/fresh-dairy/maxilact-next.html

David Cox / IDM

Print article (with images) Print article (without images)

Newsletter

Always stay up to date and sign up for our newsletter service: